Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 管理學院
  3. 會計與管理決策組
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/90606
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor劉啟群zh_TW
dc.contributor.advisorChi-Chun Liuen
dc.contributor.author林志文zh_TW
dc.contributor.authorChih-Wen Linen
dc.date.accessioned2023-10-03T16:50:01Z-
dc.date.available2023-11-09-
dc.date.copyright2023-10-03-
dc.date.issued2023-
dc.date.submitted2023-05-17-
dc.identifier.citation中文參考文獻:
1. 曹景翔,2011,台灣新創事業發展現狀與展望.
2. 陳明哲,1988,動態競爭理論.
3. 曾偉琦,2020,美容醫學診所差異化策略和求治者滿意度分析:A診所之個案研究,國立臺灣大學。
4. 溫肇東, et al.,2007,新創事業在台灣. 臺北市: 遠流.
5. 蔡瀅璇,2012,探討新創事業-商業模式與績效之關係,國立成功大學。
6. 尤映清,2022,減重自費處方藥之策略行銷分析,國立政治大學。
7. 李素雯,2021,台灣生技新創事業募資需求與募資過程之探討,國立中央大學。
8. 林詩芸,2017,新創事業的策略發展討論-以A公司為例,臺灣大學。
9. 胡竹如,2022,減重醫療院所新事業發展策略-以A院所為例,胡竹如。
10. 胡秋江, et al. 2014. 新創企業商業模式創新:投資扮演之角色. 2014創新研究國際學術研討會.
11. 張博智,2017,半監督式運動處方於南台灣病態性肥胖病患接受胃袖狀切除手術後心肺適能、身體組成改變與減重成效之關聯:一年成果分析,高雄醫學大學。
12. 楊士弘,2019,新創事業競爭策略與智慧財產權策略規劃之研究 - 以發展創新技術或服務之新創事業為例,淡江大學。
13. 詹欣隆,2012,運用資訊科技於健康管理之成效探討 -以某健檢中心體重管理門診為例,台灣大學。
14. 趙尉妘,2022,醫療機構引入醫療器材經營策略之探討-以某醫學中心之調制中頻電刺激器應用於自費減重塑身為例,義守大學。
15. 劉秀琴,2023,避重就輕:影響減重成效關鍵因素之探討-以EMBA學生為例,國立成功大學。
16. 世界衛生組織,2021,肥胖和過重, https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight,搜尋日期:2023年3月
17. 宋天洲,2017,纖體健康管理中心營運模式之研究,國立中山大學。
18. 張子清,2022,世衛組織警告:肥胖是歐洲的「流行病」, https://www.rti.org.tw/news/view/id/2131806,搜尋日期:2023年3月
19. 富昱生化科技,2021,2021運動興起,代餐起飛? 減重保健食品最新趨勢看這裡!!, https://www.fuelife.com/weight-loss-health-food/,搜尋日期:2023年3月
20. 游淑媛,2017,荷蘭飲食行為量表應用於臺灣正常體重、 肥胖族群與減重手術族群之飲食行為研究,東吳大學。
21. 黃羽彤,2015,有氧運動與營養教育介入對大學過重女學生減重及體適能之影響,義守大學。
22. 經理人月刊,2022,五力分析是什麼?幫助檢視產業競爭的五力分析法,定義、範例一次看懂!, https://www.managertoday.com.tw/articles/view/1740?,搜尋日期:2023年3月
23. 潘文涵,2004,肥胖臨床診斷與治療(第一版). 台北市: 台灣肥胖醫學會.
24. 蔡宜靜,2014,探討運用雲端資訊科技對孕期自我健康管理之成效,國立成功大學。
25. 衛生福利部,2021,109年國人死因統計結果, https://www.mohw.gov.tw/cp-5017-61533-1.html,搜尋日期:2023年3月
26. 衛生福利部國民健康署,2023,成人肥胖防治實證指引(1011102005). 台灣: 衛生福利部國民健康署.
27. 衛生福利部統計處,2021,健康促進統計年報, https://www.hpa.gov.tw/Pages/List.aspx?nodeid=118,搜尋日期:2023年3月
28. 駱晁翊,2019,應用食品營養資訊於體重管理之行動社群網站的研發,南華大學。
29. Lin, C.D.,2020,「商業模式九宮格」?商模建構之創業人必看!為客戶創造價值及鎖定目標客戶, https://blog.daoteng.org/何謂-商業模式理論-創業第一步看這邊,搜尋日期:2023年3月
30. 高偉育,2021,病態性肥胖病人接受減重手術之非酒精性脂肪肝的臨床與基礎研究,臺北醫學大學。
英文參考文獻:
1. Abu Dayyeh, B.K., et al. 2022. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet. 400(10350): 441-451.
2. Almalki, O.M., et al. 2018. Revisional Gastric Bypass for Failed Restrictive Procedures: Comparison of Single-Anastomosis (Mini-) and Roux-en-Y Gastric Bypass. Obes Surg. 28(4): 970-975.
3. Apovian, C.M., et al. 2013. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 21(5): 935-43.
4. Avgerinos, K.I., et al. 2019. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 92: 121-135.
5. Bhide, A.,2000,The Origin and Evolution of New Businesses. New York: Oxford University Press.
6. Bogers, R.P., et al. 2007. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med. 167(16): 1720-8.
7. Campbell, A. and R. Park,2005,The Growth Gamble: When Leaders Should Bet Big On New Business And How They Can Avoid Expensive Failures. England: Natl Book Network.
8. Daneschvar, H.L., M.D. Aronson, and G.W. Smetana. 2016. FDA-Approved Anti-Obesity Drugs in the United States. Am J Med. 129(8): 879 e1-6.
9. Davies, M., et al. 2021. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 397(10278): 971-984.
10. Davies, M.J., et al. 2015. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 314(7): 687-99.
11. Deurenberg, P., M. Yap, and W.A. van Staveren. 1998. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord. 22(12): 1164-71.
12. Donnelly, J.E., et al. 2009. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 41(2): 459-71.
13. Greenway, F.L., et al. 2010. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 376(9741): 595-605.
14. Hedjoudje, A., et al. 2020. Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 18(5): 1043-1053 e4.
15. Ignat, M., et al. 2017. Randomized trial of Roux-en-Y gastric bypass versus sleeve gastrectomy in achieving excess weight loss. Br J Surg. 104(3): 248-256.
16. Kyrgiou, M., et al. 2017. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 356: j477.
17. le Roux, C.W., et al. 2017. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 389(10077): 1399-1409.
18. Lumpkin, G.T. and G.G. Dess. 1996. Clarifying the Entrepreneurial Orientation Construct and Linking It to Performance. The Academy of Management Review. 21(1): 135-172.
19. McTigue, K.M., et al. 2020. Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass: The National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study. JAMA Surg. 155(5): e200087.
20. O'Neil, P.M., et al. 2018. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 392(10148): 637-649.
21. Osterwalder, A., et al.,2014,Value Proposition Design: How to Create Products and Services Customers Want. USA: Wiley.
22. Osterwalder, A., et al.,2010,Business Model Generation. USA: Wiley.
23. Peter, F.D.,1985,Innovation and entrepreneurship:Practice and principles. London: Heinemann.
24. Pi-Sunyer, X., et al. 2015. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 373(1): 11-22.
25. Porter, M.E. 1979. How competitive forces shape strategy. Harvard Business Review. March–April 1979: 1-10.
26. Porter, M.E.,1980,Competitive Strategy. The Free Press. New York.
27. Ranasinghe, P., et al. 2017. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review. BMC Public Health. 17(1): 101.
28. Raynor, H.A. and C.M. Champagne. 2016. Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults. J Acad Nutr Diet. 116(1): 129-147.
29. Renehan, A.G., et al. 2008. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 371(9612): 569-78.
30. Rubino, D., et al. 2021. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 325(14): 1414-1425.
31. Salminen, P., et al. 2018. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial. JAMA. 319(3): 241-254.
32. Sharaiha, R.Z., et al. 2021. Five-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity. Clin Gastroenterol Hepatol. 19(5): 1051-1057 e2.
33. Teece, D.J. 2010. Business Models, Business Strategy and Innovation. Long Range Planning. 43(2-3): 172-194.
34. Tsapas, A., et al. 2021. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab. 23(9): 2116-2124.
35. Villareal, D.T., et al. 2011. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 364(13): 1218-29.
36. Weghuber, D., et al. 2022. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 387(24): 2245-2257.
37. Wiklunda, J. and D. Shepherd. 2005. Entrepreneurial orientation and small business performance: a configurational approach. Journal of Business Venturing. 20: 71–91.
38. Yang, J., et al. 2015. Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index. Nat Genet. 47(10): 1114-20.
-
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/90606-
dc.description.abstract肥胖健康醫療產業是一個快速成長的產業,肥胖已成為台灣及全球性的健康問題。本文研究目的為新創事業A診所在肥胖健康醫療產業的未來營運策略,透過鑽石模型來建立診所的使命及核心價值、波特五力來分析競爭者的威脅、商業模型九宮格來分析整體解決方案、SWOT來分析優劣勢、機會和威脅及損益表來預估未來的營收。
分析結果顯示新創事業A診所專業團隊的核心優勢在於高度專業醫療團隊、新醫療技術、高品牌知名度、高服務品質,以個人化精準醫療來治療肥胖相關疾病以降低肥胖健康風險。人力資本及專業優質人才將會是診所一個很重要的資產和經營重點,必須持續精進醫療技術水準及服務品質外,同時招募優質醫師及專業人員加入。外部環境也帶給診所許多機會和挑戰,制定好未來營運策略,藉由損益表來預估未來的營收。
新的減重藥物及技術持續進步、新興科技的影響和預防醫學趨勢的威脅,造成肥胖健康醫療產業競爭加劇,依照新創事業A診所的使命、願景和核心價值,制定好未來營運策略,減低肥胖對健康造成的風險,順勢在肥胖健康產業有穩定成長的獲利。
zh_TW
dc.description.abstractObesity health medical industry is a rapidly growing industry, and obesity has become a health problem in Taiwan and the world. The research purpose is the future operation strategy of the start-up business A clinic in the obesity health medical industry, through the diamond model to establish the mission and core value, Porter's five forces to analyze the threat of competitors, and the business model to analyze the overall solution, SWOT to analyze strengths, weaknesses, opportunities and threats, and income statement to estimate future revenue.
The analysis results show that the core strengths of the professional team of the start-up business A clinic are highly professional medical team, new medical technology, high brand awareness, high service quality, and precise treatment of obesity-related diseases to reduce the health risk of obesity. Human capital and professional high-quality talents will be a very important asset and business focus of the professional team of Clinic A. It is necessary to continuously improve the level of medical technology and service quality, and at the same time recruit high-quality doctors and professionals. It is necessary to formulate future operating strategies and use the income statement to estimate future revenue.
The continuous progress of new weight loss drugs and technologies, the impact of emerging technologies, the discovery of obesity genes and the threat of preventive medicine trends have resulted in intensified competition in the obesity health medical industry. According to the mission, vision and core values of the new venture A clinic, the future operation strategy is to reduce the health risks caused by obesity and increase profits in the obesity health industry.
en
dc.description.provenanceSubmitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-10-03T16:50:01Z
No. of bitstreams: 0
en
dc.description.provenanceMade available in DSpace on 2023-10-03T16:50:01Z (GMT). No. of bitstreams: 0en
dc.description.tableofcontents國立臺灣大學碩士學位論文口試委員會審定書 i
致謝 ii
中文摘要 iii
THESIS ABSTRACT iv
圖目錄 viii
表目錄 ix
第一章、緒論 1
第一節、研究背景 1
第二節、研究問題 2
第三節、研究架構 2
第二章、文獻探討 4
第一節、產業概況 4
第二節、文獻回顧 10
第三節、理論架構 22
第三章、研究方法 26
第一節、研究方法 26
第二節、研究對象 27
第三節、研究流程 28
第四章、研究結果 30
第一節、專業團隊成立 30
第二節、波特五力分析和PEST分析 35
第三節、專業醫療團隊商業模式 42
第四節、A診所專業團隊的SWOT分析 48
第五節、A診所的未來營運策略及預估損益表 53
第六節、A診所(內科減重為主)未來營運策略及預估損益表 69
第七節、A診所決策結論之基礎 79
第五章、研究結論 83
第一節、研究結論 83
第二節、研究限制 87
第三節、未來展望 87
參考文獻 88
-
dc.language.isozh_TW-
dc.title新創事業A診所在肥胖健康醫療產業的未來營運策略:A診所個案研究zh_TW
dc.titleA Start-up Business Clinic A on the Future Operation Strategy in Obesity Health Medical Industry:Case Study of Clinic Aen
dc.typeThesis-
dc.date.schoolyear111-2-
dc.description.degree碩士-
dc.contributor.coadvisor尤琳蕙zh_TW
dc.contributor.coadvisorLin-Hui Yuen
dc.contributor.oralexamcommittee陳聖賢;俞明德zh_TW
dc.contributor.oralexamcommitteeSheng-Syan Chen;Min-Teh Yuen
dc.subject.keyword肥胖健康醫療,新創事業,精準醫療,鑽石模型,波特五力,SWOT架構,zh_TW
dc.subject.keywordObesity health medical,Start-ups business,Precision medicine,Diamond model,Porter's five forces,SWOT,en
dc.relation.page94-
dc.identifier.doi10.6342/NTU202300805-
dc.rights.note同意授權(限校園內公開)-
dc.date.accepted2023-05-18-
dc.contributor.author-college管理學院-
dc.contributor.author-dept碩士在職專班會計與管理決策組-
dc.date.embargo-lift2028-05-16-
顯示於系所單位:會計與管理決策組

文件中的檔案:
檔案 大小格式 
ntu-111-2.pdf
  目前未授權公開取用
4.15 MBAdobe PDF檢視/開啟
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved